½ÃÀ庸°í¼­
»óǰÄÚµå
1726415

¼¼°èÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® - Á¦Ç°º°, ±â¼úº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Long Read Sequencing Market Size, Share & Trends Analysis Report By Product, By Technology (Nanopore Sequencing), By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

·Õ¸®µå ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 15¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, 2025-2030³â 20.12%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ½ÃÄö½Ì¹ýÀº ÀǾàǰÀÇ °³Æí¿¡ À־ °¡Àå Áß¿äÇÑ °ÍÀ¸·Î ³ªÅ¸³ª°í Àֱ⠶§¹®¿¡ ·Õ¸®µå ½ÃÄö½ºÀÇ Áö½Ä È®´ë¿¡ ´ëÇÑ ´©ÀûµÈ ½ÃÀå°¡Ä¡µµ Á¸ÀçÇÕ´Ï´Ù. ±¸Á¶ º¯Çü ºÐ¼®¿¡ ÀÌ·¯ÇÑ ±â¼úÀ» äÅÃÇÏ´Â °æ¿ì°¡ Áõ°¡Çϰí ÀÖ¾î ¿¹Ãø ±â°£À» ÅëÇØ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇöÀç ¸¹Àº ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Á¦Á¶¾÷ü°¡ »õ·Ó°í ¼±ÁøÀûÀÎ ·Õ¸®µå ½ÃÄö½Ì¸¦ °³¹ßÇÒ ¶§ ¾à°£ À¯¸®ÇÒ °ÍÀ¸·Î ¿¹ÃøµÊ°ú µ¿½Ã¿¡ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀåÀÇ ´Ù¸¥ ¸¹Àº Àü¸ÁÀ» °³Ã´ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ´õ¿íÀÌ, ÇöÀç ÁøÇà ÁßÀÎ COVID-19 ÆÒµ¥¹ÍÀ» À§ÇØ, ÁÖ¿ä ±â¾÷Àº ¼¼°è °øÁß º¸°Ç ¿¬±¸¼Ò ¹× ¿¬±¸ÀÚ¿Í Çù·ÂÇÏ¿© ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º SARS-CoV-2ÀÇ ½Å¼ÓÇÑ ¼ø¼­¿¡ ÀÇÇØ ÇöÀç COVID-19 ÆÒµ¥¹ÍÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

°¢ ȸ»ç´Â ¶ÇÇÑ »ùÇÃÀÇ ´Ù¾çÇÑ º´¿øÃ¼¸¦ Ư¼ºÈ­ÇÏ´Â ¿öÅ© ÇÃ·Î¿ì °³¹ß¿¡ Á¾»çÇϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù µ¿Çâ¿¡¼­´Â ¿Á½ºÆ÷µå ³ª³ëÆ÷¾î Å×Å©³î·ÎÁö½º»ç°¡ »ç½º-CoV-2¸¦ °ËÃâÇϱâ À§ÇÑ ½ºÄÉÀÏ·¯ºíÇϰí Àúºñ¿ëÀÇ ½Å¼ÓÇÑ ¾î¼¼ÀÌÀÎ ·¥Æ÷¾î¸¦ °³¹ßÇß½À´Ï´Ù. À¯ÀüÀÚ Áúȯ À¯º´·ü »ó½Â°ú ·Õ¸®µå ½ÃÄö½º ±â¼ú¿¡ ´ëÇÑ 1À§ ¾÷üÀÇ ¿¬±¸°³¹ßºñ Áõ°¡°¡ ¸Â¹°·Á ÀÌ ¾÷°è´Â Å©°Ô ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ·Õ¸®µå ±â¼úÀº Áúȯ À¯ÀüÀÚ ÀÚ¸®°¡ ÀÌ¹Ì ¾Ë·ÁÁ® Àְųª °­ÇÏ°Ô ÀǽɵǴ À¯Àü¼º Áúȯ ¿¬±¸¿¡ ÁÖ·Î »ç¿ëµË´Ï´Ù.

°Ô´Ù°¡, Â÷¼¼´ë ½ÃÄö¼­¿¡ ±âÃÊÇÑ ÀÓ»ó Áúȯ ¿¬±¸ÀÇ ÇѰè´Â ÀÌ·¯ÇÑ ±â¼ú¿¡ ÀÇÇØ ºÎºÐÀûÀ¸·Î ±Øº¹µÉ ¼ö ÀÖ½À´Ï´Ù. DNA 1ºÐÀڷκÎÅÍÀÇ ´õ ±ä ¸®µå°¡ »ç¿ëµÇ±â ¶§¹®¿¡ ·Õ¸®µå ½ÃÄö½Ì ¹æ¹ýÀº ´Ù¸¥ ±â¼úº¸´Ù ºÐ¸íÈ÷ À¯¸®ÇÕ´Ï´Ù. ½ÃÀå È®´ëÀÇ ¶Ç ´Ù¸¥ ÃËÁø ¿äÀÎÀº ÀÇ·á Áø´ÜÀ» À§ÇÑ Çö´ëÀû ±â¹ýÀÌ ¹Þ¾Æµé¿©Áö°í ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. LRS ±â¼úÀÇ °¡¿ë¼º°ú ½Ç½Ã°£ ¼Óµµ´Â ´õ¿í ¼ö¿ä Áõ°¡ÀÇ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

°Ô´Ù°¡, ¿°»öü ¼¾Æ®·Î¹Ì¾îÀÇ Á¤È®ÇÑ ÂüÁ¶ Áöµµ¸¦ ÀÛ¼ºÇϱâ À§Çؼ­µµ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ¹ÙÀÌ¿À Å×Å©³î·ÎÁö ±â¾÷ÀÌ, ¶óÀ̺귯¸® Á¶Á¦¿¡ ´ëÇÑ »õ·Î¿î Á¢±Ù°ú À¯Àüü ÇØ¼®À» À§ÇÑ ÅøÀ» Á¶ÇÕÇÑ ÃÖ÷´Ü ±â¼úÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ¸¹Àº Á¶»ç¿¡¼­ LRS ±â¼úÀº À¯ÀüÀû ±â¿øÀÌ ºÒºÐ¸íÇÑ Àΰ£ Áúȯ¿¡¼­ ½Å±Ô À¯ÇØ º¯À̸¦ ½Äº°ÇÏ´Â µ¥ ¸Å¿ì À¯¿ëÇÏ´Ù´Â °ÍÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. À̰ÍÀº, ¿¬±¸ÀÚ°¡ Àü °Ô³ð ½ÃÄö½º(WGS) ±â¼úÀ» ÀÌ¿ëÇØ À¯Àü ÀÇÇÐÀ» ¹ßÀü½Ãų °¡´É¼ºÀ» dzºÎÇÏ°Ô Á¦°øÇϰí ÀÖ½À´Ï´Ù.

·Õ¸®µå ½ÃÄö½Ì ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2024³â, ¼Ò¸ðǰ ºÎ¹®ÀÌ 62.17%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • 2024³â, ³ª³ëÆ÷¾î ½ÃÄö½Ì ºÎ¹®ÀÌ 56.47%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • 2024³â ½ÃÄö½Ì ºÎ¹®Àº 62.24%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ µ¿ÇâÀº ¿¹Ãø ±â°£À» ÅëÇØ °è¼ÓµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • 2024³â ·Õ¸®µå ½ÃÄö½Ì ½ÃÀåÀº Àüü À¯Àüü ½ÃÄö½Ì ºÎ¹®ÀÌ 29.97%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • 2024³â¿¡´Â Çмú¿¬±¸±â°ü ºÎ¹®ÀÌ 48.83%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» ȹµæÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : º¯µ¿ ¿äÀÎ, °æÇâ ¹× ¹üÀ§

  • ½ÃÀå ¿¬°ü Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¾÷°è ºÐ¼® Åø
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå Á¦Ç°º° ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : Á¦Ç°º° º¯µ¿ ºÐ¼®
  • ÀåÄ¡
    • ÀåÄ¡ ½ÃÀå(2018-2030³â)
  • ¼Ò¸ðǰ
    • ¼Ò¸ðǰ ½ÃÀå(2018-2030³â)
  • ¼­ºñ½º
    • ¼­ºñ½º ½ÃÀå(2018-2030³â)

Á¦5Àå ±â¼úº° ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ±â¼úº° º¯µ¿ ºÐ¼®
  • ´ÜÀÏ ºÐÀÚ ½Ç½Ã°£ ½ÃÄö½Ì
    • ´ÜÀÏ ºÐÀÚ ½Ç½Ã°£ ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
  • ³ª³ëÆ÷¾î ½ÃÄö½Ì
    • ³ª³ëÆ÷¾î ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
  • ±âŸ
    • ±âŸ ±â¼ú ½ÃÀå(2018-2030³â)

Á¦6Àå ¿öÅ©Ç÷ο캰 ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ¿öÅ©ÇÃ·Î¿ì º¯µ¿ ºÐ¼®
  • »çÀü ½ÃÄö½Ì
    • ÇÁ¸®½ÃÄö½Ì ½ÃÀå(2018-2030³â)
  • ½ÃÄö½Ì
    • ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
  • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå(2018-2030³â)

Á¦7Àå ¿ëµµº° ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ¿ëµµº° º¯µ¿ ºÐ¼®
  • Àüü À¯Àüü ½ÃÄö½Ì
    • Àü À¯Àüü ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
  • Ÿ°Ù ½ÃÄö½Ì
    • Ÿ°Ù ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
  • ±ºÀ¯ÀüüÇÐ
    • ±ºÀ¯ÀüüÇÐ ½ÃÀå(2018-2030³â)
  • RNA ½ÃÄö½Ì
    • RNA ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
  • Èļº À¯ÀüÇÐ
    • ¿¡ÇÇÁ¦³×ƽ½º ½ÃÀå(2018-2030³â)
  • ±âŸ
    • ±âŸ ½ÃÀå(2018-2030³â)

Á¦8Àå ÃÖÁ¾ ¿ëµµº° ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµº° º¯µ¿ ºÐ¼®
  • Çмú¿¬±¸±â°ü
    • Çмú¿¬±¸±â°ü ½ÃÀå(2018-2030³â)
  • º´¿ø ¹× Áø·á¼Ò
    • º´¿ø ¹× Áø·á¼Ò ½ÃÀå(2018-2030³â)
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ½ÃÀå(2018-2030³â)
  • ±âŸ
    • ±âŸ ÃÖÁ¾ ¿ëµµ ½ÃÀå(2018-2030³â)

Á¦9Àå Áö¿ªº° ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå Á¡À¯À² : Áö¿ªº°(2024³â, 2030³â)
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • À¯·´ÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå(2018-2030³â)
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ Æ÷Áö¼Ç ºÐ¼®(2024³â)
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ ¹× »óÀå ±â¾÷
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies Limited
    • Quantapore, Inc.
    • Element Biosciences
    • BGI
    • Eurofins Genomics
    • F. Hoffmann-La Roche Ltd.
    • MicrobesNG
    • Takara Bio
    • New England Biolabs
AJY 25.05.29

Long Read Sequencing Market Growth & Trends:

The global long read sequencing market size is estimated to reach USD 1.53 billion by 2030, registering to grow at a CAGR of 20.12% from 2025 to 2030 according to a new report by Grand View Research, Inc. Since the sequencing method has shown to be of utmost importance in modifying pharmaceuticals, there is also a cumulative market value for the expanding knowledge of long read sequencing. An increase in the adoption of these technologies for the analysis of structural variants is expected to drive the market throughout the forecast period.

Currently, a lot of research is being conducted which is forecast to give manufacturers a slight advantage as they develop new and advanced elongated read sequencing, as well as to open up a lot of other prospects in the long read sequencing market. Furthermore, owing to the ongoing COVID-19 pandemic, key players are working with public health laboratories and researchers around the world to support the current COVID-19 pandemic by rapid sequencing of the novel coronavirus SARS-CoV-2.

Companies are also involved in the development of workflows to characterize a wide range of pathogens in a sample. Recently, Oxford Nanopore Technologies developed LamPORE-a scalable, low-cost, rapid assay for the detection of SARS-CoV-2. A rise in the prevalence of genetic disorders combined with an increase in top manufacturers' R&D expenditures in long-read sequencing technology is projected to greatly advance the industry. The long read technique is mostly used to study genetic disorders for which disease loci are either well-known or strongly suspected.

In addition, the limitations of clinical disease research based on next-generation sequencing could be partially overcome by these technologies. Since longer reads from a single DNA molecule are used, long-read sequencing methods have a distinct advantage over other technology. Another driver of market expansion is the rising acceptance of contemporary methods for medical diagnosis. The portability and real-time speed of LRS technology are further factors contributing to its rising demand.

It is additionally utilized to create a precise reference map of the chromosome centromere. In addition, numerous biotech firms are creating cutting-edge technologies that combine a fresh approach to library preparation with tools for genomic analysis. Accordingly, a number of researches show that LRS technology is quite useful for identifying novel harmful mutations in human disorders with unidentified genetic origins. This offers a wealth of potential for researchers to use whole-genome sequencing (WGS) technology to develop medical genetics.

Long Read Sequencing Market Report Highlights:

  • In 2024, the consumables segment held the largest market share of 62.17%.
  • The nanopore sequencing segment dominated the market in 2024 with a share of 56.47%.
  • The sequencing segment accounted for the largest revenue share of 62.24% in 2024. This trend is anticipated to continue throughout the projection period.
  • The whole genome sequencing segment dominated the long read sequencing market in 2024 with a share of 29.97%.
  • In 2024, the academic & research institutes segment captured the largest market share of 48.83%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Workflow
    • 1.2.4. Application
    • 1.2.5. End-use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advantages Offered By Long Read Sequencing Techniques
      • 3.2.1.2. Increasing Applications In Clinical Sequencing And Analysis
      • 3.2.1.3. Advancements In Data Analysis Platforms
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Error Rates Of Long Read Technologies
      • 3.2.2.2. Technological Challenges Associated With Long Read Techniques
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Long Read Sequencing Market: Product Movement Analysis
  • 4.3. Instruments
    • 4.3.1. Instruments Market, 2018 - 2030 (USD Million)
  • 4.4. Consumables
    • 4.4.1. Consumables Market, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Long Read Sequencing Market: Technology Movement Analysis
  • 5.3. Single Molecule Real Time Sequencing
    • 5.3.1. Single Molecule Real Time Sequencing Market, 2018 - 2030 (USD Million)
  • 5.4. Nanopore Sequencing
    • 5.4.1. Nanopore Sequencing Market, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Other Technologies Market, 2018 - 2030 (USD Million)

Chapter 6. Workflow Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. Long Read Sequencing Market: Workflow Movement Analysis
  • 6.3. Pre-sequencing
    • 6.3.1. Pre-sequencing Market, 2018 - 2030 (USD Million)
  • 6.4. Sequencing
    • 6.4.1. Sequencing Market, 2018 - 2030 (USD Million)
  • 6.5. Data Analysis
    • 6.5.1. Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. Long Read Sequencing Market: Application Movement Analysis
  • 7.3. Whole Genome Sequencing
    • 7.3.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 7.4. Targeted Sequencing
    • 7.4.1. Targeted Sequencing Market, 2018 - 2030 (USD Million)
  • 7.5. Metagenomics
    • 7.5.1. Metagenomics Market, 2018 - 2030 (USD Million)
  • 7.6. RNA Sequencing
    • 7.6.1. RNA Sequencing Market, 2018 - 2030 (USD Million)
  • 7.7. Epigenetics
    • 7.7.1. Epigenetics Market, 2018 - 2030 (USD Million)
  • 7.8. Others
    • 7.8.1. Other Applications Market, 2018 - 2030 (USD Million)

Chapter 8. End-Use Business Analysis

  • 8.1. Segment Dashboard
  • 8.2. Long Read Sequencing Market: End-use Movement Analysis
  • 8.3. Academic & Research Institutes
    • 8.3.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 8.4. Hospitals & Clinics
    • 8.4.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
  • 8.5. Pharmaceutical & Biotechnology Companies
    • 8.5.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Other End-use Market, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis

  • 9.1. Segment Dashboard
  • 9.2. Long Read Sequencing Market Share By Region, 2024 & 2030
  • 9.3. North America
    • 9.3.1. North America Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Competitive Scenario
      • 9.3.2.3. Regulatory Framework
      • 9.3.2.4. U.S. Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Competitive Scenario
      • 9.3.3.3. Regulatory Framework
      • 9.3.3.4. Canada Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Competitive Scenario
      • 9.3.4.3. Regulatory Framework
      • 9.3.4.4. Mexico Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.2. UK
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Competitive Scenario
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. UK Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.3. Germany
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Competitive Scenario
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Germany Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Competitive Scenario
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. France Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Competitive Scenario
      • 9.4.5.3. Regulatory Framework
      • 9.4.5.4. Italy Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Competitive Scenario
      • 9.4.6.3. Regulatory Framework
      • 9.4.6.4. Spain Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Competitive Scenario
      • 9.4.7.3. Regulatory Framework
      • 9.4.7.4. Denmark Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key Country Dynamics
      • 9.4.8.2. Competitive Scenario
      • 9.4.8.3. Regulatory Framework
      • 9.4.8.4. Sweden Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.9. Norway
      • 9.4.9.1. Key Country Dynamics
      • 9.4.9.2. Competitive Scenario
      • 9.4.9.3. Regulatory Framework
      • 9.4.9.4. Norway Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Japan Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Competitive Scenario
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. China Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Competitive Scenario
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. India Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.5. Australia
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Competitive Scenario
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. Australia Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Competitive Scenario
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Thailand Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.7. South Korea
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Competitive Scenario
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. South Korea Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Brazil Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Argentina Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Competitive Scenario
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. South Africa Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Competitive Scenario
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Saudi Arabia Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Competitive Scenario
      • 9.7.4.3. Regulatory Framework
      • 9.7.4.4. UAE Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key Country Dynamics
      • 9.7.5.2. Competitive Scenario
      • 9.7.5.3. Regulatory Framework
      • 9.7.5.4. Kuwait Long Read Sequencing Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Position Analysis, 2024
  • 10.4. Company Profiles/Listing
    • 10.4.1. Pacific Biosciences of California, Inc.
      • 10.4.1.1. Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Strategic Initiatives
    • 10.4.2. Oxford Nanopore Technologies Limited
      • 10.4.2.1. Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Strategic Initiatives
    • 10.4.3. Quantapore, Inc.
      • 10.4.3.1. Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Strategic Initiatives
    • 10.4.4. Element Biosciences
      • 10.4.4.1. Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Strategic Initiatives
    • 10.4.5. BGI
      • 10.4.5.1. Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Strategic Initiatives
    • 10.4.6. Eurofins Genomics
      • 10.4.6.1. Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Strategic Initiatives
    • 10.4.7. F. Hoffmann-La Roche Ltd.
      • 10.4.7.1. Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Strategic Initiatives
    • 10.4.8. MicrobesNG
      • 10.4.8.1. Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Strategic Initiatives
    • 10.4.9. Takara Bio
      • 10.4.9.1. Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Strategic Initiatives
    • 10.4.10. New England Biolabs
      • 10.4.10.1. Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Strategic Initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦